Objec0ves. Next Genera0on Biomarkers in Prostate Cancer. UBC Department of Urologic Sciences. Jennifer Locke, R2 January 28, 2015
|
|
- August Armstrong
- 6 years ago
- Views:
Transcription
1 UBC Department of Urologic Sciences Next Genera0on Biomarkers in Prostate Cancer Jennifer Locke, R2 January 28, 2015 Objec0ves 1. Highlight why biomarkers are important in prostate cancer management 2. Iden0fy key clinical scenarios where biomarkers offer the most relevance 3. Highlight some of the new 0ssue, blood, urine and image- based biomarkers 4. Describe the future of the next genera0on biomarkers 1
2 The role of PSA in prostate cancer management The Randomised Study of Screening for Prostate Cancer (ERSPC) The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Schroder FH. Lancet Andriole GL. J Natl Cancer Inst Defini0ons Prognos0c biomarker provides informa0on on the likely course of the disease in an untreated individual Predic0ve biomarker can be used to iden0fy subpopula0ons of pa0ents who are most likely to respond to a given therapy Brunner N. Connec0ons
3 Key clinical scenarios for biomarkers in prostate cancer How do we dis0nguish aggressive disease from indolent disease in pa0ents on ac#ve surveillance (AS)? How do we iden0fy pa0ents with localized prostate cancer who will benefit from radia0on therapy post- radical prostatectomy? How do we select and sequence drugs for pa0ents with castra#on- resistant prostate cancer (CRPC) in the context of several recently approved new agents? Tissue- based gene signatures Myriad Gene0cs Prolaris Score TM Genome Health OncotypeDx TM Genomic Prostate Score (GPS) GenomeDx Biosciences Decipher TM NF- kb ac0vated recurrence predictor 21 (NARP21) 3
4 Myriad Gene0cs Prolaris Score TM 31 to 46- gene RNA expression signature in formalin- fixed paraffin- embedded (FFPE) biopsy specimens Clinical Evidence Predictor of biochemical relapse (BCR) acer radical prostatectomy (RP) in 3 cohorts of CaP pa0ents (n=582). Predictor of BCR acer external beam radia0on therapy (EBRT) in 141 CaP pa0ents. Predictor of overall survival (OS) especially when combined CAPRA- S* score in 413 CaP pa0ents. Bishoff JT. J Urol Cuzick J. Br J Cancer Cooperberg MR. J Clini Oncol Freedland SK. Int J Radiot Oncol Biol Phys Myriad Gene0cs Prolaris Score TM Kaplan- Meier plots of biochemical progression- free probability by cell- cycle progression (CCP) scores (Prolaris Score TM ) grouped the subset of pa0ents who were intermediate or high risk by clinical criteria defined by CAPRA- S score 3. With or without adjustment for clinical variables, increasing CCP score (Prolaris Score TM ), both as a con#nuous and categorized variable, was associated with markedly higher hazard ra#os for progression (con#nuous HR 2.1, 95% CI , P<0.001). CCP=cell- cycle progression score Cooperberg MR. J Clini Oncol
5 Genome Health OncotypeDx TM Genomic Prostate Score (GPS) 17- gene RNA expression signature in FFPE biopsy specimens Clinical Evidence Predictor of suitability for ac0ve surveillance in 441 RP and 562 biopsy specimens from men with low and intermediate risk. In the same popula0on the addi0on of GPS was shown to reclassify many men stra0fied to high risk based on CAPRA- S 6 alone. Pa0ents with both high GPS and high CAPRA- S risk scores were at markedly elevated post- RP risk for lethal CaP. Cooperberg MR. Eur Urol Klein EA. Eur Urol Knezevic D. BMC Genomics Genome Health OncotypeDx TM Genomic Prostate Score (GPS) Cumula0ve incidence of prostate cancer specific mortality (CSM) for the CAPRA- S high- risk stra0fied by genomic classifier (GPS). For pa#ents with both high CAPRA- S and high genomic classifier (GPS) scores, the cumula#ve incidence of CSM was 45% at 10 yrs. Cooperberg MR. Eur Urol
6 GenomeDx Biosciences Decipher TM 22- gene RNA expression signature in FFPE RP specimens Clinical Evidence Predictor of early metastasis in 545 high- risk RP pa0ents. Predictor of metastasis in 1010 high- risk RP pa0ents. Erho N. PLoS Ross AE. Prostate Cancer Prosta0c Dis Karnes RJ J Urol Den RB. Radiat Oncol Bio Phys Badani KK. BJU Int GenomeDx Biosciences Decipher TM Metastasis Risk at 5 yrs ~1 in 4 Popula#on Prevalence 19% 20% 10% ~1 in 17 21% 0% ~1 in 42 60% # at Risk Karnes RJ. J Urol
7 GenomeDx Biosciences Decipher TM Clinical Evidence Predictor of BCR and metastasis in 139 high- risk RP pa0ents post- adjuvant radia0on. Predictor of early metastasis in 219 high- risk RP pa0ents, especially when combined with CAPRA- S score. Predictor of early metastasis in 85 men with BCR acer RP. Erho N. PLoS Ross AE. Prostate Cancer Prosta0c Dis Karnes RJ J Urol Den RB. Radiat Oncol Bio Phys Badani KK. BJU Int GenomeDx Biosciences Decipher TM Clinical Evidence Decipher TM results affect decision making with respect to post- RP adjuvant radia0on clinical u0lity tes0ng. Badani KK. BJU Int
8 NF- kb ac0vated recurrence predictor gene signature in RP specimens Clinical Evidence Predictor of metastasis- free and disease specific survival in previously publically archived dataset of 596 RP samples. Jin R. Cancer Res NF- kb ac0vated recurrence predictor 21 Kaplan Meier plot for the systemic metastasis- free survival of pa0ents with prostate cancer who had lymph node metastasis at the 0me of RRP surgery. Survival analyses showed that the NF- kb signature predicts significant differences in the distant metastasis- free survival of the pa#ents that had lymph node metastasis at the #me of surgery (HR = 2.1; 95% CI, ; P = ). Jin R. Cancer Res
9 Tissue- based gene signatures The Prolaris Score TM and the OncotypeDx TM can be used in prostate biopsy 0ssue to iden0fy adverse pathologic features that predict those pa0ents who may benefit from ac0ve interven0on rather than ac0ve surveillance. Prognos0c. Decipher TM, the Prolaris Score TM and the NF- kb signature have been designed to predict clinical outcome acer radical prostatectomy. Prognos0c. Decipher TM has been validated in mul0ple cohorts and has demonstrated poten0al to influence the clinical decision to recommend radia0on post- radical prostatectomy. Tissue- based gene signatures A cri0cal considera0on for 0ssue markers in prostate cancer is under sampling of the prostate with the risk of missing a more threatening tumour. All of these markers have been developed in retrospec0ve studies. Op0mal clinical valida0on to prove clinical u0lity will require prospec0ve clinical trials. Cost may be a factor in decision making. 9
10 Tissue- based gene signatures Tissue- based gene Signature Cost per pa0ent (US) Prolaris Score TM Oncotype Dx TM GPS GenomeDx Decipher TM NF- kb gene signature $3400 $3800 $4250* - hlp://prostate- cancer.org/wp- content/uploads/insights/august2013/insights_august2013_%20new_biomarker_test.pdf Blood- based biomarkers microrna cell- free DNA Circula0ng tumour cells 10
11 microrna Small noncoding RNAs found in 0ssue and serum samples that are involved in post- transcrip0onal regula0on of a large number of biological processes. Sample microrna mrna microrna induce gene silencing by binding to target sites found within the 3 UTR of the targeted mrna micrornas are involved in a wide range of biological processes such as cell cycle control, apoptosis and several developmental and physiological processes hlp:// are- micrornas. Diagnosis Ac#ve Surveillance Serum mir- 141 is associated with higher GS in 170 pa0ents undergoing prostate biopsy. Serum mir- 16 levels is useful in discrimina#ng CaP from BPH in 47 pa0ents undergoing biopsy. In serum higher mir levels are correlated with CaP diagnosis in a series of pa0ents (78 with CaP and 28 without CaP). microrna Disease progression Localized Prostate Cancer A serum signature of 2-3 differen0ally expressed mirs had a high posi0ve predic0ve value for biochemical failure in 105 CaP pa0ents at 0me of RP. Serum mir- 182 expression is associated with biochemical and clinical progression free survival in various samples (60 RP, 273 biopsies, and 92 urine) from CaP pa0ents. CRPC Serum mir- 375, mir- 141 are significantly overexpressed in 30 high risk localized CaP pa0ents and 26 metasta#c CRPC pa0ents. Higher serum mirna signature is associated with worse outcome on docetaxel chemotherapy in 97 CRPC pa0ents. Bryant RJ. Br J Cancer Westermann AM. An0cancer Res Nguyen HC. Prostate Lichner Z. Clin Chem Lin HM. Br J Cancer De Malos- Arruda L. Nat Rev Clin Oncol Den RB. Radiat Oncol Biol Phys
12 Cell- free DNA Small amounts of cell- free DNA in plasma, which likely originates from cancer cells and, therefore, might cons0tute source of gene0c material for the iden0fica0on of tumour- associated molecular altera0ons. Sample dying tumour cells release small pieces of their DNA into the bloodstream known as cell- free DNA screening cell- free DNA for soma0c muta0ons can be used to detect and follow the progression of a pa0ent's tumour hlp:// hlp:// Diagnosis Ac#ve Surveillance There was a significant differences in cell- free DNA levels in CaP versus BPH pa0ents. Higher cell- free DNA levels are significantly correlated with tumour stage and category in 81 CaP pa0ents. Cell- free DNA Disease progression Localized Prostate Cancer A significantly shorter biochemical recurrence free survival is associated with at least one value above 140ng/ ml of cell- free DNA in 133 pa0ents with CaP as compared to 33 controls. CRPC The presence of the androgen receptor (AR) gene aberra0on in cell- free DNA is correlated with radiographic and clinical disease progression on enzalutamide (AR directed therapy). The detec0on of AR gain and AR L702H muta0on in cell- free DNA is associated with resistance to abiraterone. A muta0on in F876L detected in cell- free DNA was associated with resistance to novel drug ARN Schwarzenbach H. Clin Cancer Res Dawson SJ. N Eng J Med hlp://mee0nglibrary.asco.org/ content Carreira S. Sci Transl Med Joseph JD. Cancer Discov
13 Circula0ng tumour cells (CTCs) Rare circula0ng cancer cells in the peripheral blood that may have an important role in tumour dissemina0on and progression. Sample pooled CTCs Metastasis Primary Single cell CTC- capture technologies* genomic, transcriptomic, proteomic, and metabolomic profiles of individual CTCs reveal mechanisms of disease progression Barradas AM. Nat Biotechnol De Malos- Arruda L. Nat Rev Clin Oncol Circula0ng tumour cells Diagnosis Ac#ve Localized Surveillance Prostate Cancer CTC detec0on is rare in 12 pa0ents with localized CaP. Disease progression CTC CD117 levels decrease acer radical prostatectomy and increase again in pa0ents who have biochemical recurrence. CRPC Unfavorable pretreatment CTC counts are predic#ve of shorter overall survival in 231 pa0ents with progressive CRPC pa0ents. Baseline CTC counts are well correlated with overall survival in 100 pa0ents with CRPC. Higher CTC counts are associated with overall survival in 57 pa0ents treated with docetaxel. High CTC counts are associated with high risk of death in 276 pa0ents with metasta0c CaP (IMMC38 trial). Higher CTC counts were observed in pa0ents with bone metastasis rela0ve to those with soc 0ssue disease (n=120 pa0ents with CRPC). CTC with AR- V7 posi0vity are associated with lower PSA response rates, shorter PSA progression free survival and shorter overall survival in 31 CRPC enzalutamide- treated pa0ents and 31 CRPC abiraterone- treated pa0ents. Kling J. Nat Biotechnol Lin BK. Biomicrofluidics Kerr BA. Oncotarget Khrana KK. Cur Urol de Bono JS. Clin Cancer Res Scher HI. Lancel Oncol Miyamoto DT. Nat Rev Clin Oncol Okegawa T. An0cancer Res
14 CTCs - limita0ons The major limita0on impac0ng the clinical u0lity of CTCs is not having sufficient DNA capture due to low CTC numbers in biological samples. Current plavorms can also be limited by their selec0vity and ability to extract the separated cells. New technologies are being validated to overcome this shortcoming. Placorms for the capture of CTCs EpCAM- affinity based CellSearch system AdnaTest BreastCancerDetect CTC- Chip Dynal MACS MagSweeper On- Q- Ity CTC- ETI Physical proper0es- based ISET ScreenCell ApoStream Density Gradient Centrifuga0on Other methods FAST EPISPOT Flow cytometry (FACS) PRO Onc Assay Barradas AM. Nat Biotechnol De Malos- Arruda L. Nat Rev Clin Oncol Blood- based biomarkers microrna can be used to predict outcome in pa0ents on docetaxel chemotherapy. Prognos0c and Predic0ve. cell- free DNA can be used to predict resistance to enzalutamide, abiraterone and ARN Predic0ve. CTCs can be used to prognos0cate disease and predict response to enzalutamide and abiraterone. Prognos0c and Predic0ve. 14
15 Blood- based biomarkers Blood- based biomarkers have the poten0al to overcome the inherent heterogeneity of CaP and capture the tumour characteris0cs in their en0rety. Blood- based biomarkers fulfill the goal of a liquid biopsy, enabling non- invasive, real- 0me monitoring of disease status and response to therapy, especially in the context of metasta0c CRPC. Using blood- based biomarkers we are able to monitor molecular changes in response to therapy. Thus we are able to monitor drug targets and guide corresponding altera0ons in therapy; the essence of precision oncology. Urine- based biomarkers PCA3 TMPRSS2- ERG Metabolin Prostarix TM 15
16 PCA3 CaP- specific gene located on chromosome 9q21-22 that can be detected in urine samples. Clinical Evidence The urine PCA3 assay demonstrated a sensi0vity of 69% and specificity of 79% for predic0ng CaP diagnosis in 143 men undergoing biopsy. Marks LS. Urology Badani KK. BJU Int Antonoarakis ES. N Engl J Med Deras IL. J Urol PCA3 Clinical Evidence Urine PCA3 levels were predic0ve of those pa0ents who need a repeat biopsy in men who have elevated PSA and a prior nega0ve biopsy. For biopsy- naïve pa0ents, a high PCA3 level increases the probability that an ini0al prostate biopsy will iden0fy cancer. Higher urine PCA3 levels are associated with higher volume CaP and high- grade disease in 387 men on an ac0ve surveillance protocol. Badani KK. BJU Int Antonoarakis ES. N Engl J Med Deras IL. J Urol Wei JT. J Clin Oncol
17 TMPRSS2- ERG Gene fusion involving the 5 untranslated region of the androgen- regulated gene TMPRSS2 with ERG or ETV1 that can be detected in urine samples. Clinical Evidence TMPRSS2- ERG detec0on has yielded a specificity of 93% and a posi0ve predic0ve value of 94% for the diagnosis of CaP in 78 men with PSA >3ng/mL and/or abnormal DRE. Casanova- Salas I. J Urol Tomlins SA. Neoplasia Lin DW. Clin Cancer Res TMPRSS2- ERG Clinical Evidence TMPRSS2- ERG detec0on independently predicted Gleason score and clinical tumour stage in 497 men undergoing biopsy. TMPRSS2- ERG score is associated with higher volume CaP and high- grade disease in 387 men on an ac0ve surveillance protocol. Casanova- Salas I. J Urol Tomlins SA. Neoplasia Lin DW. Clin Cancer Res
18 Metabolin Prostarix TM Four metabolite signature detected in urine by liquid chromatography mass spectrometry. Diagnosis Ac#ve Surveillance Biopsy Prostarix TM score was associated with increased risk of CaP in 1122 pa0ents. Disease progression Localized Prostate Cancer RP Prostarix TM score was associated with disease free survival rates in 148 CaP pa0ents. CRPC Urine Prostarix TM score was associated with metastases in pa0ents with CaP (bone metastases n=20, normal bone n=14, malignant prostate 0ssue n=13, benign prostate 0ssue n=17 and plasma samples n=15). McDunn JE. Prostate Koutros S. Carcinogenesis Goodman OB. Cancer Epidemiol Biomarkers Prev Danila DC. Clin Cancer Res Urine- based biomarkers The PCA3 assay can be used to predict need for repeat biopsy in men who have elevated PSA and a prior nega0ve biopsy. Prognos0c. The Prostarix TM score can be used to stra0fy the risk of a pa0ent with previous nega0ve biopsy for occult cancer. Prognos0c. The Prostarix TM score can be used to predict for disease free survival and metastasis. Prognos0c. 18
19 Urine- based biomarkers Urine- based biomarkers are available in large quan00es and can be collected non- invasively. Urine- based biomarkers are par0cularly alrac0ve when the prostate is intact, especially in the seng of screening and early stage disease. MRI PET/CT Image- based biomarkers 19
20 MRI Disease progression Diagnosis MRI can help guide repeat biopsy in pa0ents with previously nega0ve biopsy and elevated PSA. Ac#ve Surveillance Localized Prostate MRI is important in Cancer staging with reduc0on in the risk of missing occult higher- risk disease. MRI is used to assess for extraprosta#c extension prior to radical prostatectomy. CRPC MRI predicted biochemical relapse acer radical prostatectomy and metastas0c disease progression. Sciarra A. BJU Int Hoeks CM. Eur Urol Hambrock T. J Urol Hoeks CM. Invest Radiol Baco E. Eur Urol Rud E. World J Urol Somford DM. J Urol Agner SC. Radiology MRI MRI images of a 76M with four nega0ve biopsies and a PSA of 329. Picchio M. Eur J Nucl Med Mol Imaging
21 Diagnosis PET has not proven useful in differen0a0ng biopsy- proven CaP from BPH. PET/CT Disease progression Ac#ve Surveillance Localized Prostate Cancer CRPC (11)C- choline PET/CT before salvage radia0on therapy during the early phase of biochemical relapse helps select pa0ents who may benefit from this aggressive treatment. 18F- fluorocholine PET/CT may be u0lized in biochemical relapse of prostate cancer acer radical treatment, with an overall disease detec0on rate close to 50%. Reske SN. J Nucl Med Scher B. Eur J Mucl Med Castellucci P. J Nucl Med Rodado- Marina S. BJU Int Image- based biomarkers MRI provides clinical u0lity in diagnosis, ac0ve surveillance, localized prostate cancer and CRPC sengs in conjunc0on with other biomarkers. PET may provide clinical u0lity in the CRPC seng. 21
22 Image- based biomarkers U0liza0on of MRI for quan0ta0ve image analysis is a novel concept that is in the early stages of development: Comparison of enhanced appearance and textural features of triple- nega0ve cancer and fibroadenoma Comparison of dynamic enhanced appearance and textural discrimina0on between triple- nega0ve cancer (TN) in 52- year- old woman and ER- posi0ve cancer in 55- year- old woman Quan0ta0ve image analysis can also be used to measure tumour response to therapy, which in turn can guide clinical decision- making. Agner SC. Radiology Key clinical scenarios for biomarkers in prostate cancer How do we dis0nguish aggressive disease from indolent disease in pa0ents on ac#ve surveillance (AS)? How do we iden0fy pa0ents with localized prostate cancer who will benefit from radia0on therapy post- radical prostatectomy? How do we select and sequence drugs for pa0ents with CRPC in the context of several recently approved new agents? 22
23 Diagnosis Blood- based microrna and cell- free DNA can be used to discriminate CaP from BPH. Prognos0c. Urine PCA3 can prognos0cate need for repeat biopsy in men who have elevated PSA and a prior nega0ve biopsy. Prognos0c. Urine Prostarix TM can stra0fy risk of occult cancer in men with previous nega0ve biopsy. Prognos0c. Ac0ve Surveillance Tissue- based gene signatures (e.g. Prolaris Score, OncotypeDx ) can iden0fy pa0ents on ac0ve surveillance who may harbor occult higher- risk disease warran0ng defini0ve interven0on. Prognos0c. Image- based MRI can help focus repeat biopsy on specific prosta0c lesions. Prognos0c. 23
24 Localized Prostate Cancer Tissue- based gene signatures (e.g. Decipher ) can predict recurrence and progression acer RP and help determine if the pa0ent may benefit from adjuvant radia0on therapy. Prognos0c. Blood- based microrna can predict biochemical and clinical progression. Prognos0c. Blood- based cell- free DNA can predict biochemical recurrence. Prognos0c. CRPC Blood- based microrna can predict outcome on docetaxel chemotherapy. Prognos0c and Predic0ve. Blood- based cell- free DNA can predict resistance to enzalutamide, abiraterone and ARN Predic0ve. Blood- based circula0ng tumour cells can prognos0cate disease progression and predict response to enzalutamide and abiraterone. Prognos0c and Predic0ve. Urine Prostarix TM score can prognos0cate for metastases. Prognos0c. Image- based MRI, PET/CT can predict for biochemical relapse. Prognos0c. 24
25 The Future of Biomarkers in Prostate Cancer Future technology must focus on improving biomarker assay robustness. Paterlini- Bréchot. Cancer Microenvironment, The Future of Biomarkers in Prostate Cancer With the novel agents arising in the management of CRPC disease the use of easily accessible urine and blood- based biomarkers will bloom. The development of microrna, cell- free DNA and CTCs technologies for urine and blood samples will be instrumental to predic0ng specific therapy outcome and op0mizing sequen0al use of these novel agents in the treatment of pa0ents with CRPC. 25
26 The Future of Biomarkers in Prostate Cancer Two significant barriers: the need for careful clinical valida0on, the associated costs to the system. Incorpora0ng of these biomarkers into ongoing and future clinical trials will be essen0al in developing and implemen0ng them in clinic. Clinical Valida0on Vasan RS. Circula0on
27 Tissue Tissue- based gene Signature Cost per pa0ent (US) Associated Costs Prolaris Score TM OncotypeDx TM GPS GenomeDx Decipher TM NF- kb gene signature $3400 $3800 $4250* - Blood CTCs $ assay + $35.11 interpreta0on fee (Medicare Fee; covered in roughly half of the US) Urine PCA3 $385 Image? The Future of Biomarkers in Prostate Cancer Two significant barriers: the need for careful clinical valida0on, the associated costs to the system. Incorpora0ng of these biomarkers into ongoing and future clinical trials will be essen0al in developing and implemen0ng them in clinic. 27
28 Acknowledgements Dr. Peter Black Dr. Richard Wassersug Defini0ons Accuracy - The degree of agreement between the results of a measurement and the true value of the measurement. Precision - The degree of agreement between independent test results obtained under s0pulated condi0ons. Clinical (diagnos#c) sensi#vity - The propor0on of pa0ents with a well- defined clinical disorder whose test values are posi0ve or exceed a defined decision limit. Clinical (diagnos#c) specificity - The propor0on of pa0ents who do not have a specified clinical disorder whose test results are nega0ve or within the defined decision limit. Gutman S. Nature Review Cancer
29 Defini0ons Effec#veness - The use of the device for its intended uses and condi0ons of use, when accompanied by adequate direc0ons for use and warnings against unsafe use, will provide clinically significant results in a significant por0on of the target popula0on. Safety - The probable benefit to health from use of the device for its intended uses and condi0ons of use, when accompanied by adequate direc0ons and warnings against unsafe use, will outweigh any probable risk. Gutman S. Nature Review Cancer
30 Rela0onship between biomarker publica0ons and patents Drucker E. Genome Medicine Drucker E. Genome Medicine
31 A prognos0c DNA signature for prostate cancer Mul0variate Cox propor0onal hazard model adjus0ng for clinical covariates (Gleason score and pretreatment PSA) in the low- risk and intermediate- risk groups (A) and when applied to the full pooled radical prostatectomy cohort (n=271) the signature for copy number altera0on iden0fies pa0ents who will fail rapidly (B). Lalonde E. Lancet Oncology
Providing Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPersonalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017
Personalizing prostate cancer care: A clinical perspective on imaging and other biomarkers in 2017 Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics @dr_coops Osher
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationResolving the PSA testing controversy. Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg
Resolving the PSA testing controversy Professor Villis Marshall AC Professor Bruce Armstrong AM Professor Mark Frydenberg Professor Villis Marshall AC Introduc)on Guidelines aim to inform tes)ng for the
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More informationMultigene Testing in Prostate Cancer Risk Stratification
Multigene Testing in Prostate Cancer Risk Stratification Ashley Ross, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Objectives Briefly review relevant molecular biology of localized
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationHow will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationUpdates on Use of Radiopharmaceu3cals in Clinical Trials August 22, 2017
Updates on Use of Radiopharmaceu3cals in Clinical Trials August 22, 2017 Evan Y. Yu, M.D. Professor of Medicine (Oncology) University of Washington Fred Hutchinson Cancer Research Center Discussion Topics
More informationRadical prostate surgery?
Decipher enables personalized and actionable treatment after surgery Radical prostate surgery? The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationUTILIZATION OF ONCOTYPE DX TO GUIDE TREATMENT FOR EARLY STAGE BREAST CANCER. Rosemary Cress, DrPH
UTILIZATION OF ONCOTYPE DX TO GUIDE TREATMENT FOR EARLY STAGE BREAST CANCER Rosemary Cress, DrPH June 16, 2015 Introduction Therapy for women with early stage breast cancer typically includes, surgery
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationC. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
More informationThe Who s of Genomic Markers: Whom to Biopsy?
The Who s of Genomic Markers: Whom to Biopsy? 1.15.17 7:20-7:40 AM E. David Crawford, M.D. Professor of Surgery/Urology/ Radiation Oncology University of Colorado WSJ 5.10.16 2 Recent Advances in Prostate
More informationAn Approach to Early Detection of Significant Cancers
An Approach to Early Detection of Significant Cancers FDUS 9.11.16 E. David Crawford, M.D. University of Colorado Denver Aurora, CO AUA State of Art 2 WSJ 5.10.16 3 Recent Advances in Prostate Cancer:
More informationA Genomic Approach to Active Surveillance
A Genomic Approach to Active Surveillance Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Cleveland Clinic Disclosures
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationBiologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University
Biologic Subtypes and Prognos5c Factors Claudine Isaacs, MD Georgetown University Prognos5c Factor Defini5on Predicts outcome in absence of systemic therapy Thus tell us when (not how) to treat a pa5ent
More informationCorporate Medical Policy
Corporate Medical Policy Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_and_protein_biomarkers_for_diagnosis_and_risk_assessment_of_prostate_cancer
More informationThe Role of PCP in Prostate Cancer Screening Beaver Creek Ma< T. Rosenberg
The Role of PCP in Prostate Cancer Screening Beaver Creek 2017 Ma< T. Rosenberg A Cri@cal Look at the Historical Flow Pa@ent concern Office visit History DRE PSA Biopsy Specimen with pathologist Too Many
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationCarcinoma mammario triple nega0ve Nuove acquisizioni biologiche. Giuseppe Curigliano MD PhD UNIMI & IEO
Carcinoma mammario triple nega0ve Nuove acquisizioni biologiche Giuseppe Curigliano MD PhD UNIMI & IEO Outline San Antonio Breast Cancer Symposium, December 5-9, 2017 The year of DNA Repair targe?ng Olaparib
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationReliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
More informationGene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Policy Number: 2.04.111 Last Review: 04/2018 Origination: 04/2014 Next Review: 04/2019 Policy Blue Cross and Blue Shield
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationMP Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
Medical Policy MP 2.04.111 BCBSA Ref. Policy: 2.04.111 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.33 Genetic and Protein Biomarkers for the Diagnosis and
More informationSee Submission for References.
Guideline Page and Request PROS-1 External submission from Myriad Genetic Laboratories, Inc. requesting addition of the following statement as a distinct step immediately to the right of life expectancy
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationBiomarkers in Prostate Cancer
Biomarkers in Prostate Cancer Current clinical implications and future perspectives Rui Henrique Serviço de Anatomia Patológica e Centro de Investigação Instituto Português de Oncologia do Porto Francisco
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationBiosta's'cs Board Review. Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016
Biosta's'cs Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016 Review key biosta's'cs concepts Understand 2 X 2 tables Objec'ves By the end of this
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationDevelopment and Applica0on of Real- Time Clinical Predic0ve Models
Development and Applica0on of Real- Time Clinical Predic0ve Models Ruben Amarasingham, MD, MBA Associate Professor, UT Southwestern Medical Center AHRQ- funded R24 UT Southwestern Center for Pa?ent- Centered
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Gene Expression Profiling
More informationGenetic Tests and Genetic Counseling How to Analyze Your Own Genome
Genetic Tests and Genetic Counseling 02-223 How to Analyze Your Own Genome Genetic Tests for Huntington Disease Hun7ngton Disease Incurable brain disorder that runs in families Movement, cogni7ve, and
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationGENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT
CANCER MANAGEMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationThe Prognos+c Value of Pre- Diagnosis Health- Related Quality of Life on Survival: A Prospec+ve Cohort Study of Older Americans with Lung Cancer
The Prognos+c Value of Pre- Diagnosis Health- Related Quality of Life on Survival: A Prospec+ve Cohort Study of Older Americans with Lung Cancer Laura C. Pinheiro, Timothy M. Zagar, Bryce B. Reeve Laura
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationThe Importance of Iden0fying Women at Risk for BRCA1/2 Muta0ons for Referral to Cancer Gene0cs Services
The Importance of Iden0fying Women at Risk for BRCA1/2 Muta0ons for Referral to Cancer Gene0cs Services Cecelia Bellcross, PhD, MS, CGC Emory University School of Medicine Department of Human Gene0cs Alliance
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationActive surveillance: Shrinking the grey zone. Sommerakademi e Munich, June rd FOIUS Tel Aviv, July 2016
Active surveillance: Shrinking the grey zone Active surveillance: 3 rd FOIUS Tel Aviv, July 2016 Shrinking the grey zone Sommerakademi e Munich, June 30 2016 Active Surveillance for low risk PCa What has
More informationCurrent Findings on High Intensity Focused Ultrasound (HIFU) Thomas J Polascik, MD, FACS Professor of Surgery
Current Findings on High Intensity Focused Ultrasound (HIFU) Thomas J Polascik, MD, FACS Professor of Surgery Outline Whole gland abla6on selec6on and outcomes Focal abla6on - Eligibility and pa6ent selec6on
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationDebate: Genetics and Genomics should be used ONLY for re-biopsy
Debate: Genetics and Genomics should be used ONLY for re-biopsy Larry Goldenberg, CM, OBC, MD, FRCSC Professor, UBC Dept of Urologic Sciences Director of Development and Supportive Care, Vancouver Prostate
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationNeuroendocrine Prostate Cancer (NEPC)
Neuroendocrine Prostate Cancer (NEPC) Jehonathan H. Pinthus MD, Ph.D. Associate professor Department of Surgery- Urology McMaster University The 27th Annual Interna/onal Prostate Cancer Update (IPCU 27)
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationCardiovascular Effects of ADT in
Cardiovascular Effects of ADT in Click to edit Prostate Master Cancer /tle style Pa/ents Chris Plummer Freeman Hospital, Newcastle upon Tyne, UK Newcastle University Bri/sh Cardio- Oncology Society Click
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationProgram Guide Decipher Certification and Training Registry (Decipher CTR)
Program Guide (Decipher CTR) This Program Guide provides a step- by- step overview of the operational aspects of the Decipher CTR, including how to (1) enroll as a healthcare provider and receive training
More informationImaging of prostate cancer local recurrences : why and how?
Imaging of prostate cancer local recurrences : why and how? Olivier Rouvière Department of Urinary and Vascular Imaging Hospices Civils de Lyon Lyon - France 1. Preliminary Remarks Preliminary Remarks
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationUrine Markers for Bladder Cancer. Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia
Urine Markers for Bladder Cancer Peter Black, MD, FACS, FRCSC Khosrowshahi Family Chair Vancouver Prostate Centre University of British Columbia Disclosures Role Consultant/Speaker Grant Funding Clinical
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationMolEcular Taxonomy of BReast cancer International Consortium (METABRIC)
PERSPECTIVE 1 LARGE SCALE DATASET EXAMPLES MolEcular Taxonomy of BReast cancer International Consortium (METABRIC) BC Cancer Agency, Vancouver Samuel Aparicio, PhD FRCPath Nan and Lorraine Robertson Chair
More informationReview of the Stampede Results. Charles Ryan MD University of California San Francisco
Review of the Stampede Results Charles Ryan MD University of California San Francisco Se#ng and hypothesis Se
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More information